Sugi Predict

Sugi Predict / Compounds / SCHEMBL868555

SCHEMBL868555

SCHEMBL868555

Clc1ccc2c(n1)CNC2

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CHRNB2 P17787 1/20 0.38
▸ CHRNA4 P43681 1/20 0.38
▸ HTR2C P28335 4/20 0.36
▸ HTR2A P28223 3/20 0.36
▸ HTR2B P41595 3/20 0.36
▸ KCNH2 Q12809 1/20 0.35
▸ PNMT P11086 1/20 0.34
▸ ABHD6 Q9BV23 1/20 0.32
▸ HTR3E A5X5Y0 1/20 0.32
▸ HTR3B O95264 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ HTR3A P46098 1/20 0.32
▸ HTR3D Q70Z44 1/20 0.32
▸ HTR3C Q8WXA8 1/20 0.32
▸ SIRT2 Q8IXJ6 1/20 0.31
▸ ASIC3 Q9UHC3 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30101445 1.00 CHRNB2 (0.38) CHRNB2CHRNA4HTR2CHTR2AHTR2B
Hydrochloric Acid SCHEMBL30345777 0.98 CHRNB2 (0.37) CHRNB2CHRNA4HTR2CHTR2AHTR2B
Hydrochloric Acid SCHEMBL20723245 0.98 CHRNB2 (0.37) CHRNB2CHRNA4HTR2CHTR2AHTR2B
Trifluoroacetic Acid SCHEMBL18550357 0.83 ABHD6 (0.41) CHRNB2CHRNA4ABHD6
SCHEMBL29361127 0.82 PNMT (0.47) HTR2CHTR2AHTR2BPNMTASIC3
SCHEMBL868598 0.82 PNMT (0.47) HTR2CHTR2AHTR2BPNMTASIC3
SCHEMBL12691385 0.82 PNMT (0.47) HTR2CHTR2AHTR2BPNMTASIC3
Hydrochloric Acid SCHEMBL12541304 0.80 PNMT (0.47) HTR2CHTR2AHTR2BPNMTASIC3
Hydrochloric Acid SCHEMBL1017773 0.80 PNMT (0.46) HTR2CHTR2BPNMTASIC3
Hydrochloric Acid SCHEMBL31226197 0.80 PNMT (0.46) HTR2CHTR2BPNMTASIC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025085848-A1 ANTIBACTERIAL COMPOUNDS ARREPATH, INC. (US) 2025-04-24 — — WO disclosed
US-20240327381-A1 Compounds and Compositions for Selective Degradation of Engineered Proteins CELGENE CORPORATION (US) 2024-10-03 — — US disclosed
CN-118084936-A Three-ring-containing compound and application thereof 石药集团中奇制药技术（石家庄）有限公司 2024-05-28 — — CN disclosed
WO-2024081775-A1 SYNTHESIS OF 6-FLUORO-2-METHYLBENZO[D]THIAZOL-5-YL COMPOUNDS ELI LILLY AND COMPANY (US) 2024-04-18 — — WO disclosed
WO-2024081775-A1 SYNTHESIS OF 6-FLUORO-2-METHYLBENZO[D]THIAZOL-5-YL COMPOUNDS ELI LILLY AND COMPANY (US) 2024-04-18 — — WO disclosed
US-11912702-B2 Substituted pyridines as inhibitors of histone deacetylase ALKERMES, INC. (US) 2024-02-27 — — US disclosed
EP-3623369-B1 NOVEL MORPHOLINYL AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE HOFFMANN LA ROCHE (CH) 2023-10-25 — — EP disclosed
WO-2023067353-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2023-04-27 — — WO disclosed
CN-108368107-B Fused heterocyclic compounds as S1P modulators 艾伯维公司 2021-11-26 — — CN disclosed
US-10556907-B2 Fused heterocyclic compounds as S1P modulators AbbVie Deutschland GmbH & Co. KG (DE) 2020-02-11 — — US disclosed
US-20090203665-A1 HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES JOLIDON SYNESE 2009-08-13 — — US disclosed
US-20090203665-A1 HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES JOLIDON SYNESE 2009-08-13 — — US disclosed
US-7557114-B2 Heterocyclic-substituted phenyl methanones HOFFMAN-LA ROCHE INC. (US) 2009-07-07 — — US disclosed
US-7557114-B2 Heterocyclic-substituted phenyl methanones HOFFMAN-LA ROCHE INC. (US) 2009-07-07 — — US disclosed
US-7557114-B2 Heterocyclic-substituted phenyl methanones HOFFMAN-LA ROCHE INC. (US) 2009-07-07 — — US disclosed
CN-101119968-A Heterocyclically substituted phenyl methanone derivatives as glycine transporter 1 inhibitors HOFFMANN LA ROCHE (CH) 2008-02-06 — — CN disclosed
EP-1848694-A1 HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 F. Hoffmann-Roche AG (CH) 2007-10-31 — — EP disclosed
WO-2006082001-A1 HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 F.HOFFMANN-LA ROCHE AG (CH) 2006-08-10 — — WO disclosed
WO-2006082001-A1 HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 F.HOFFMANN-LA ROCHE AG (CH) 2006-08-10 — — WO disclosed
US-20060178381-A1 Heterocyclic-substituted phenyl methanones HOFFMANN-LA ROCHE INC. 2006-08-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203665-A1 HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES CYP2B6, CYP2D6, CYP1A2 CHRNB2 4168/4885CHRNA4 3686/4885HTR2C 235/4885
US-20060178381-A1 Heterocyclic-substituted phenyl methanones CYP2B6, CYP2D6, CYP1A2 CHRNB2 4168/4885CHRNA4 3686/4885HTR2C 235/4885
US-20240327381-A1 Compounds and Compositions for Selective Degradation of Engineered Proteins TP53, APC, MDM2 CHRNB2 4733/4885CHRNA4 4879/4885HTR2C 4330/4885
US-11912702-B2 Substituted pyridines as inhibitors of histone deacetylase HDAC2, HDAC1, HDAC3 CHRNB2 3332/4885CHRNA4 2606/4885HTR2C 1355/4885
US-10556907-B2 Fused heterocyclic compounds as S1P modulators S1PR1, S1PR2, S1PR3 CHRNB2 2225/4885CHRNA4 2019/4885HTR2C 835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.